Akoya Biosciences downgraded to Neutral from Overweight at JPMorgan

JPMorgan downgraded Akoya Biosciences to Neutral from Overweight without a price target following the Q2 report. Although the print was in line with expectations with better than expected instrument performance, Akoya reduced the revenue guide for the second quarter in a row given the continued macroeconomic pressures along with the slower pace of recovery relative to the company’s expectations throughout the quarter, the analyst tells investors in a research note. The firm believes the visibility across the company’s business remains limited given the broader macro backdrop which has pressured customers’ capital budgets.